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ABSTRACT 
  
Objective: The aim of this study was to compare oral Artemether-Lumefantrine to intravenous 
Quinine by exploring its effectiveness in cerebral malaria in hospitalized patients.  
Materials and Methods: A randomized prospective study was conducted among 64 hospitalized 
cases of cerebral malaria. One group of patients was treated with intravenous Quinine and another 
group was treated with oral Artemether-Lumefantrine. Response in clinical, laboratory parameters and 
outcome of treatment were noted every eight hours.  
Results: Oral Artemether-Lumefantrine showed almost similar response in clinical and laboratory 
parameters with median temperature (101º F), pulse rate (102 b/m), systolic BP (110mmHg), GCS 
(12), hemoglobin (9.8 g/dl), WBC (9000/µl), platelet (130000/µl), B. glucose (101 mg/dl), S. 
creatinine (1.8 mg/dl), ALT (32 U/L), mean disappearance time of parasite from blood (40 hours), and 
mean time for regaining full consciousness (30 hours). Final outcome was also similar in both drugs 
with only 1 death (3.1%) reported in each group.  
Conclusion: In cerebral malaria intravenous Quinine or oral Artemether-Lumefantrine therapy does 
not have any statistically significant difference in terms of clinical parameter, laboratory parameter 
and final outcome.  
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INTRODUCTION  
An estimated five hundred million 
people contract malaria each year 
worldwide, resulting in almost two million 
deaths yearly. 
[1]
 The Plasmodium 
falciparum parasite is responsible for almost 
all the neurological complications 
associated with malaria. In 2002, an 
estimated 2.2 billion individuals were 
exposed to Plasmodium falciparum in 
malaria endemic areas, with 515 million 
clinical episodes and over 1 million deaths. 
[2]
 The most fatal manifestation of 
Falciparum Malaria is cerebral malaria. 
Cerebral malaria if not treated, has a very 
high mortality and morbidity. By the 
widespread drug resistance the situation is 
further complicated, which is quickly 
emerging to even the new drugs.
 [3]
 The 
strict definition of cerebral malaria requires 
the presence of Plasmodium falciparum 
parasitemia with a Glasgow Coma Scale 
score of 9 or less, and other causes ruled 
out. 
[4]
  
Quinine has its primary role in the 
treatment of severe malaria. But, 
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intravenous Quinine has a narrow 
therapeutic window. Parental Quinine 
administration needs a constant rate infusion 
with dosing three times a day. 
Administration in intramuscular route is 
painful, and can cause sterile abscesses and 
predispose to lethal tetanus. 
[5]
 Although 
blindness and deafness may follow self 
poisoning, these adverse effects are rare in 
cerebral malaria; however, hypoglycaemia 
is a serious problem during patient 
management when Quinine is infused, 
especially in children and pregnant women. 
[6]
 In remote areas of developing countries 
there are not enough qualified healthcare 
personnel to manage the cerebral malaria in 
early stage of disease with intravenous 
access. Mortality increases due to delayed 
start of treatment. With appropriate and easy 
treatment protocol the mortality of cerebral 
malaria can be reduced. Oral Quinine is not 
a good option in cerebral malaria because of 
its delayed absorption and less parasite 
clearance rate within 48 hours which causes 
high mortality rate. 
[6]
 This study was 
conducted to compare the efficacy of 
intravenous quinine and oral Artemether-
Lumefantrine, the two most frequently used 
drugs for cerebral malaria and to find out 
the outcome of oral Artemether-
Lumefantrine as an effective oral 
emergency drug. 
 
MATERIALS AND METHODS  
This is a descriptive prospective 
hospital based cross sectional study done for 
one year (January 2014 to December 2014) 
in Rangamati Sadar Hospital Bangladesh 
among tribal. A full detailed history with 
proper systemic and neurological 
examination was performed by the authors. 
The diagnosis was confirmed with 
microscopic blood film examination (both 
thick and thin film) and rapid diagnostic test 
(RDT). Routine necessary laboratory tests 
were done to exclude other alternate 
diagnosis. History, clinical examination and 
laboratory investigations were recorded on 
standard forms on admission and then every 
four hourly.  
Patients were assigned two groups of 
32 patients in each group. These were 
named Quinine Group and Artemether-
Lumefantrine Group. Quinine Group 
patients were treated with Quinine 
dihydrochloride infusion (Inj. Jasoquine 
300mg/5ml amp) in the dosage of 600mg in 
500ml of 10% Dextrose water every 8 hours 
for at least seven days. Artemether-
Lumefantrine Group patients were treated 
with Artemether-Lumefantrine (Tab. 
Coartem, Artemether 20mg, Lumefantrine 
120mg) by oral or nasogastric tube 
(semiconscious or unconscious patient) in 
the dosage of 4 tablets at initial diagnosis 
and the after 8, 24 and 48 hours. Clinical 
parameters (temperature, pulse, systolic 
blood pressure, Glasgow coma scale), 
laboratory parameters (hemoglobin, WBC, 
Platelet, B. Glucose, S. Creatinine, ALT), 
mean disappearance time of plasmodium 
from blood and mean time for regaining full 
consciousness was noted every four hours. 
Side effects of drugs were also noted.  
Statistical analysis: Statistical analysis was 
made using the chi-square test for 
categorical variables. A value of p<0.05 was 
considered statistically significant. The 
Statistical Package for Social Sciences, 
SPSS (version 16.0) was used to analyze 
data.  
Ethical considerations: Institutional 
Review Board (IRB) approval was obtained 
from ethical committee of Chittagong 
Medical College and Hospital. Before 
administering the survey, investigators 
explained the purpose of the study to all 
patients and patient’s attendants if patient is 
unconscious. The voluntary nature of 
participation and the anonymous and 
confidential nature of the interview 
schedules were strongly emphasized. Verbal 
informed consent was obtained. 
 
RESULTS  
Total 64 patients were diagnosed 
with cerebral malaria and treated as 
intravenous Quinine group (32 patients) and 
oral Artemether-Lumefantrine group (32 
patients). Age group 20-40 were more 
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vulnerable to cerebral malaria (n=40). Male 
gender showed increased vulnerability 
(n=39). (Table 1) 
 
Table 1: Age and gender group treated with quinine and 
Artemether-Lumefantrine 
Age Group: Quinine Artemether-Lumefantrine 
<20 4 1 
20-40 19 21 
>40 9 10 
Gender:   
Male 21 18 
Female 11 14 
Our study revealed that there was no 
significant difference (p >0.05) in response 
to clinical parameters with Quinine and 
Artemether-Lumefantrine, Temperature, 
pulse rate, blood pressure and Glasgow 
coma scale showed improved response with 
oral Artemether-Lumefantrine which was 
almost similar to intravenous Quinine 
sulphate (Table 2). 
 
Table 2: Clinical parameter response after 48 hours 
Clinical parameter Quinine Artemether-Lumefantrine 
Temperature (ºF) 100.5 (100-101) 101 (100.5-101.5) 
Pulse rate (beats/mi) 98 (94-102) 102 (90-114) 
Blood pressure (Systolic) mm Hg 120 (110-130) 110 (90-130) 
Glasgow coma scale 12 (11-13) 12 (11-13) 
*median (IQR) estimated. (p>0.05) 
 
Table 3: Laboratory parameter response at 48 hours 
Lab parameters: Quinine Artemether-Lumefantrine 
Hemoglobin 10.5 (8.4-11.3) 9.8 (8.7-11.2) 
WBC Total count 8500 (7450-9150) 9000 (5250-11500) 
Platelet 127500 (75750-190250) 130000 (90000-200000) 
Blood Glucose 111.50 (80-140) 101 (82.5-133) 
S. Creatinine 1.4 (1.03-3.25) 1.8 (0.9-3.4) 
ALT 65 (38.75-125) 60 (37-105) 
*median (IQR) estimated. (p>0.05) 
 
We also found similarity in the 
laboratory parameters between quinine and 
Artemether-Lumefantrine which was 
recorded at 48 hours after treatment. 
Hemoglobin, WBC total count, platelet, 
blood glucose (to assess hypoglycemia), 
serum creatinine (kidney function) and ALT 
(liver enzyme) all showed improved 
response with oral Artemether-
Lumefantrine which was similar to 
intravenous Quinine. (Table 3) 
 
36
40
Quinine Artemether-Lumefantrine
Mean disappearance time (Hours)
Figure 1: Mean disappearance time of plasmodium from 
blood. 
On examining the blood slide (both 
thick and thin blood film) every 4 hourly, 
we found mean disappearance time of 
parasite plasmodium falciperum at 36 hours 
and 40 hours with Quinine and Artemether-
Lumefantrine respectively. (Figure 1) 
Mean time for regaining 
consciousness was also measured to assess 
the treatment response. The patient was 
clinically examined with continuous follow 
up. Intravenous Quinine sulphate showed 
almost similar response (28 hours) in 
comparison to oral Artemether-
Lumefantrine (30 hours). (Figure 2) 
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Mean time (Hours)
 
Figure 2: Mean time for regaining full consciousness. 
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After completion of treatment the 
outcome was measured. Full recovery rate 
was very good with both drugs. The only 
complication found after treatment was 
severe weakness with both the drugs (n=3). 
Mortality rate was very low in both Quinine 
(n=1) and Artemether-Lumefantrine (n=1). 
Hypoglycemia and vomiting are the two 
side effects found in only 2 patients treated 
with Quinine infusion. (Table 4) 
 
Table 4: Final outcome with quinine and Artemether-Lumefantrine 
Final outcome Quinine 
n (%) 
Artemether-Lumefantrine 
n (%) 
Fully Recovered 30 (93.8) 29 (90.6) 
Recovered with complications 1 (3.1) 2 (6.3) 
Death 1 (3.1) 1 (3.1) 
Side effects of drugs 2 (6.3) 0 (0.0) 
 
DISCUSSION 
Quinine is the standard drug used for 
the treatment of cerebral malaria. 
Artemether- Lumefantrine combination is a 
new product and claimed to be more 
effective in cerebral malaria. Both drugs 
showed comparable results in this study and 
is consistent with others published reports 
and further studies confirmed these results. 
[7,8]
 Our study is comparable and almost 
equivalent to the study conducted earlier in 
China. 
[9]
 Mean disappearance time of 
plasmodium from blood and the mean time 
for regaining full consciousness with 
Artemether- Lumefantrine showed similar 
result with the study done in China. 
[9]
 This 
life-saving benefit of Artemether-
Lumefantrine compared with Quinine in 
severe malaria has to derive from its greater 
intrinsic parasiticidal activity. The principal 
pharmacodynamic advantage of 
Artemether-Lumefantrine is that it has a 
much broader stage-specificity of action 
than does quinine. It kills circulating ring-
stage parasites before they can 
mature, which reduces sequestration of 
infected erythrocytes in the venules and 
capillaries of vital organs and thereby 
prevents potentially lethal microvascular 
obstruction. 
[10]
 The large and consistent 
reduction in mortality associated with 
Artemether-Lumefantrine and the consistent 
finding that mortality reduction is greatest in 
hyperparasitemia, lends support to the 
central quantitative role of parasitised 
erythrocyte sequestration in the pathology 
of malaria. 
[11]
 Any delay in treating severe 
infection will increase mortality. The ease 
and safety of oral Artemether-Lumefantrine 
is important practical advantages. 
Artemether-Lumefantrine is more expensive 
to buy, but quinine is more expensive to 
administer. 
Cerebral malaria treatment is 
considered equivalent to Quinine therapy 
and probably this concept has not changed 
over the years. When resistance to 
Chloroquine was reported from almost 
every part of the world a devastating 
situation was created. At that time the only 
option left was quinine for cerebral malaria. 
Unfortunately intravenous Quinine is not 
available due to the lack of trained 
healthcare personnel in remote areas of 
developing and underdeveloped countries. 
Delay in hospital admission and starting 
treatment increases mortality. The only 
option left then is early start of treatment 
with oral administration. With early oral 
administration of Artemether- Lumefantrine 
both mortality and morbidity can be reduced 
by almost equal response to intravenous 
quinine in clinical and laboratory result. 
 
CONCLUSION 
Oral Artemether-Lumefantrine is an 
excellent drug when administered early in 
patients with cerebral malaria. In 
comparison with intravenous Quinine it 
showed almost same outcome in clinical and 
laboratory parameters with less side effects. 
So, oral Artemether-Lumefantrine can be 
considered as a second line treatment option 
in cerebral malaria when intravenous 
Quinine is not available. 
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